Home
|
Inbox
|
Search
|
View Abstract
Clinical Impacts of Hepatotoxicity of Anti-Tuberculosis Therapy
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A5559 - Clinical Impacts of Hepatotoxicity of Anti-Tuberculosis Therapy
Author Block: J. Lee1, J. Song2, J. L. Lee1, J. Park1, E. Heo1, D. Kim1, H. S. Chung1; 1Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of, 2Seoul National University Hospital, Seoul, Korea, Republic of.
Background: There are limited data regarding whether drug induced hepatotoxicity (DIH) may affect the clinical outcome of tuberculosis (TB) treatment. We aimed to elucidate the effect of DIH on the clinical course and outcomes of pulmonary TB. Methods: In a retrospective cohort study, we included patients with culture-proven pulmonary TB who were treated in a tertiary hospital from 2013 to 2016. DIH was defined as the criteria proposed in the official ATS statements. We compared the clinical outcomes including treatment success rate and time-to-sputum culture conversion between DIH and non-DIH patients. Results: Of 170 TB patients who were included, 22 cases (12.9%) were diagnosed as DIH. Patients with DIH had significantly higher age and Charlson comorbidity index, higher proportion of chronic liver disease and chronic alcoholics, and lower body mass index. There was no significant difference in the treatment success rate and 2-month sputum culture conversion rate between DIH and non-DIH patients. However, actual treatment time/planned treatment time ratio and treatment interruption time/total treatment time ratio were significantly higher in DIH patients. Conclusion: DIH does not lead to significant differences in the clinical outcomes of pulmonary TB treatment despite the discontinuation and/or prolongation of treatment.
Author Block: J. Lee1, J. Song2, J. L. Lee1, J. Park1, E. Heo1, D. Kim1, H. S. Chung1; 1Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of, 2Seoul National University Hospital, Seoul, Korea, Republic of.
Background: There are limited data regarding whether drug induced hepatotoxicity (DIH) may affect the clinical outcome of tuberculosis (TB) treatment. We aimed to elucidate the effect of DIH on the clinical course and outcomes of pulmonary TB. Methods: In a retrospective cohort study, we included patients with culture-proven pulmonary TB who were treated in a tertiary hospital from 2013 to 2016. DIH was defined as the criteria proposed in the official ATS statements. We compared the clinical outcomes including treatment success rate and time-to-sputum culture conversion between DIH and non-DIH patients. Results: Of 170 TB patients who were included, 22 cases (12.9%) were diagnosed as DIH. Patients with DIH had significantly higher age and Charlson comorbidity index, higher proportion of chronic liver disease and chronic alcoholics, and lower body mass index. There was no significant difference in the treatment success rate and 2-month sputum culture conversion rate between DIH and non-DIH patients. However, actual treatment time/planned treatment time ratio and treatment interruption time/total treatment time ratio were significantly higher in DIH patients. Conclusion: DIH does not lead to significant differences in the clinical outcomes of pulmonary TB treatment despite the discontinuation and/or prolongation of treatment.
|
Home
|
Inbox
|
Search
|